AKI Clinical Trial
Official title:
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
The purpose of this study is to better understand if transesophageal echocardiography during cardiac surgery can predict problems with kidney function after cardiac surgery.
Informed consent will be obtained prior to surgery. Preoperative demographic and baseline clinical data will be collected. We will assess the patient's risk of postoperative AKI using the validated Cleveland clinic score based on preoperative risk factors and calculate the European System Operative Score Risk Evaluation score (EuroSCORE II). After standard anesthesia induction and intubation, a TEE probe will be inserted by a cardiac anesthesiologist, who is certified in intraoperative echocardiography. We will use a standard ultrasound machine (EPIQ 7 Philips;Philips, Bothell, WA). Images of the right or left kidney along with Doppler flow and velocities will be obtained prior to cardiopulmonary bypass (CPB), after CPB, and after chest closure. Images of the portal vein with Doppler flow and velocity will be obtained prior to CPB, after CPB, and after chest closure. Vitals signs and hemodynamic data will be collected concurrently during these times. (See Data Sheet) Concurrent ECG will be obtained to identify the phases of the cardiac cycle. Mean arterial pressure (MAP) will be maintained within 20% of baseline MAP with bolus or continuous infusion of vasopressors (phenylephrine, norepinephrine, epinephrine, vasopressin, ephedrine). Cardiopulmonary bypass management will be standard, with target systemic blood flow of 2.4L/min/m2. Postoperative data will include urine output, serum creatinine, calculated GFR (using Modification of Diet in Renal Disease [MDRD] method) hospital and ICU length of stay, and 30-day mortality. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
Recruiting |
NCT04597034 -
Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19
|
N/A | |
Completed |
NCT04458571 -
Effect of CRRT Duration on Solute Removal
|
||
Recruiting |
NCT04114747 -
Renal Physiology During Continuous Renal Replacement Therapy
|
N/A | |
Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT05382078 -
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
Completed |
NCT04762524 -
The Impact of CRRT Modality on Filter Life
|
N/A | |
Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
Completed |
NCT04788394 -
Renal Involvement in Hospitalized Children With COVID-19
|
||
Recruiting |
NCT04474249 -
Follow-up of Critical COVID-19 Patients
|
||
Completed |
NCT04407156 -
Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
|
||
Completed |
NCT04517630 -
Renal Biomarkers in AKI and COVID-19
|
||
Recruiting |
NCT04895384 -
El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
|
||
Completed |
NCT03070353 -
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
|
Phase 2/Phase 3 | |
Completed |
NCT03391830 -
Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy
|
N/A |